Investigational New Drugs

, 26:355

Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles

Authors

  • Sharon L. Sanborn
    • Division of Hematology and OncologyUniversity Hospitals Case Medical Center, Case Comprehensive Cancer Center
    • Division of Hematology and OncologyUniversity Hospitals Case Medical Center, Case Comprehensive Cancer Center
  • Afshin Dowlati
    • Division of Hematology and OncologyUniversity Hospitals Case Medical Center, Case Comprehensive Cancer Center
  • Joanna M. Brell
    • Division of Hematology and OncologyUniversity Hospitals Case Medical Center, Case Comprehensive Cancer Center
  • Smitha Krishnamurthi
    • Division of Hematology and OncologyUniversity Hospitals Case Medical Center, Case Comprehensive Cancer Center
  • Joseph Gibbons
    • Division of Hematology and OncologyUniversity Hospitals Case Medical Center, Case Comprehensive Cancer Center
  • Joseph A. Bokar
    • Division of Hematology and OncologyUniversity Hospitals Case Medical Center, Case Comprehensive Cancer Center
  • Charles Nock
    • Division of Hematology and OncologyUniversity Hospitals Case Medical Center, Case Comprehensive Cancer Center
  • Anne Ness
    • Division of Hematology and OncologyUniversity Hospitals Case Medical Center, Case Comprehensive Cancer Center
  • Scot C. Remick
    • Mary Babb Randolph Cancer CenterWest Virginia University
PHASE I STUDIES

DOI: 10.1007/s10637-008-9137-0

Cite this article as:
Sanborn, S.L., Cooney, M.M., Dowlati, A. et al. Invest New Drugs (2008) 26: 355. doi:10.1007/s10637-008-9137-0

Summary

Purpose: Pre-clinical models have demonstrated the benefit of metronomic schedules of cytotoxic chemotherapy combined with anti-angiogenic compounds. This trial was undertaken to determine the toxicity of a low dose regimen using docetaxel and thalidomide. Patients and Methods: Patients with advanced solid tumors were enrolled. Thalidomide 100mg twice daily was given with escalating doses of docetaxel from 10 to 30mg/m2/week. One cycle consisted of 12 consecutive weeks of therapy. The maximal tolerated dose (MTD) was defined as the dose of thalidomide along with docetaxel that caused ≤grade 1 non-hematologic or ≤grade 2 hematologic toxicity for cycle one. Results: Twenty-six patients were enrolled. Dose-limiting toxicities (DLTs) were bradycardia, fatigue, fever, hyperbilirubinemia, leukopenia, myocardial infarction, and neutropenia. Prolonged freedom from disease progression was observed in 44.4% of the evaluable patients. Conclusions: This anti-angiogenic regimen was well tolerated and demonstrated clinical benefit. The recommended phase II dosing schedule is thalidomide 100mg twice daily with docetaxel 25mg/m2/week.

Keywords

MetronomicDocetaxelThalidomideAngiogenesisPhase I

Copyright information

© Springer Science+Business Media, LLC 2008